Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Metsera - What They Never Told You

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

The Economic Times

Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.

International Business Times

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

MarketBeat

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

Benzinga

Markets exhale as Novo Nordisk withdraws from Metsera bidding war

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.

Euronews

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy

For the previous edition of Deal Dispatch, click here.

Benzinga

Novo Nordisk wants to keep its crown leading the weight-loss drugs pack. Despite outlook downgrades and lawsuits, its CFO has a plan

“The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.

Fortune

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

International Business Times

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

The Guardian - UK

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Benzinga

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle

On Friday, Pfizer Inc. (NYSE:PFE) filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk (NYSE:NVO) in a Delaware Court.

International Business Times

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

The Independent UK

Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

The Independent UK

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Guardian - UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

Benzinga

Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial

Metsera, Inc. (NASDAQ:MTSR) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i with potential for monthly dosing.

MarketBeat

Pfizer is Locking in New Growth Through a New Acquisition

Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.

The Independent UK

Asian shares trade mixed after US stocks set more records

Asian shares are trading mixed in the absence of key market-driving news in the region, after a seemingly relentless rally continued on Wall Street

International Business Times UK

Metsera Stock Rockets After Pfizer's $7.3b — Should You Still Invest?

Metsera stock has soared after Pfizer announced a $7.3 billion acquisition, sparking investor buzz. Analysts are now weighing whether the biotech rally has more room to run or if buyers should stay cautious.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.